IMERYS CLAYS, INC. – Trademark Portfolio

Entity Type: 03

IMERYS CLAYS, INC. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include PLATINUM, ASTRA-GLAZE, and ASTRA-PLATE. The owner is based in ROSWELL, GA.

100 MANSELL COURT, SUITE 300

ROSWELL, GA 30076

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

IMERYS CLAYS, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (6 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does IMERYS CLAYS, INC. have?

IMERYS CLAYS, INC. has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 2 cancelled.

What trademark classes does IMERYS CLAYS, INC. file in?

IMERYS CLAYS, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are IMERYS CLAYS, INC.'s most well-known trademarks?

IMERYS CLAYS, INC.'s registered trademark portfolio includes well-known marks such as PLATINUM, ASTRA-GLAZE, and ASTRA-PLATE. These are among 3 currently registered trademarks in the portfolio.

What is IMERYS CLAYS, INC.'s trademark registration success rate?

IMERYS CLAYS, INC. has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.